Translational Medicine Guide transforms drug development processes: the recent Merck experience

Area of Science:

• Drug development
• Translational medicine
• Biomarker research

Background:

• Merck is implementing a new question-based Translational Medicine Guide (TxM Guide).
• The TxM Guide is integrated into the drug development process starting at lead optimization.
• This initiative aims to enhance early-stage drug development strategies.

Purpose of the Study:

• To evaluate the initial experiences and impact of the TxM Guide.
• To identify opportunities for improving target understanding, dose setting, and patient selection.
• To assess the guide's influence on organizational learning, costs, and governance.

Main Methods:

• The TxM Guide is embedded within integrated development plans for each program.
• Focus on utilizing early human-based evidence, biomarkers, and simulations.
• Continuous evaluation of the guide's effectiveness throughout the drug development lifecycle.

Main Results:

• Improved target understanding, therapeutic index determination, and patient subpopulation selection.
• Increased utilization of biomarkers and simulations in early development.
• Enhanced organizational learning, cost-efficiency, and governance within drug development programs.

Conclusions:

• The TxM Guide offers significant benefits for optimizing drug development.
• There is a need for enhanced external resources for biomarker validation and clinical utility.
• Further development is required for natural disease history tracking and biobanking support.